Confirming the dynamism in this field, RPE65 gene replacement for Leber congenital amaurosis (LCA) [1] is now in Phase I/II clinical trials driven by three different teams all using AAV2/2 vectors [2]–[5]. The gene discussed is RPE65; the disease is Leber congenital amaurosis.